Abstract
To ascertain whether CD4(+) lymphocyte increases induced by interleukin (IL)-2 enhanced in vivo immune responses, 38 human immunodeficiency virus (HIV)-infected patients who had received highly active antiretroviral therapy (HAART) or HAART and IL-2 for at least 60 weeks were immunized with tetanus toxoid, inactivated glycoprotein 120-depleted HIV-1, and hepatitis A and B vaccines. Despite dramatic increases in CD4(+) lymphocyte counts, IL-2 did not enhance immunization responses.
Publication types
-
Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
AIDS Vaccines / immunology
-
Adjuvants, Immunologic / pharmacology
-
Adult
-
Anti-HIV Agents / therapeutic use
-
Antiretroviral Therapy, Highly Active
-
CD4 Lymphocyte Count
-
CD4-Positive T-Lymphocytes / cytology*
-
CD4-Positive T-Lymphocytes / drug effects*
-
CD4-Positive T-Lymphocytes / immunology
-
Drug Therapy, Combination
-
HIV Infections / drug therapy
-
HIV Infections / immunology*
-
Hepatitis A Vaccines / immunology
-
Hepatitis B Vaccines / immunology
-
Humans
-
Interleukin-2 / pharmacology*
-
Lymphocyte Activation / drug effects*
-
Male
-
Tetanus Toxoid / immunology
Substances
-
AIDS Vaccines
-
Adjuvants, Immunologic
-
Anti-HIV Agents
-
Hepatitis A Vaccines
-
Hepatitis B Vaccines
-
Interleukin-2
-
Tetanus Toxoid